RE: RE: RE: RE: conspiTheory - Slide 17Thanks for this "ilikeslide 17 for prostate cancer knowing that MCC can help."
In fact, Endo has nothing in its current products or pipeline adressing prostate cancer but we all know that (1) BNC has something (2) and that Endo has some rights on this application of MCC. Did Indevus have something like that in their portfolio ?
And abpout the delays, remember that in the last conference, they said that they are now ready to answer to FDA's concern about Aveed -
in the Dec 3 2009 ... "In the complete response letter, the FDA has requested information from Endo to address the agency's concerns regarding very rare but serious adverse events, including post-injection anaphylactic reaction and pulmonary oil microembolism. The letter also specified that the proposed Risk Evaluation and Mitigation Strategy (REMS) is not sufficient."
--> how long did it took to get prepared to amswer this FDA concern ? June 2010 - Dec 2009 = 6 months+ - and this answer is not yet completed
So, if they publish MCC data in september, it will mean +- 5 months after 1 year the last patient received his first treatment. This data analysis is probably not a blind compilation of data received by the Committee... 1 or 2 more months is not that significant.